JONES EVAN/ FA

Director Evan Jones sold 43,196 shares for $1,946,287.73 across 6 transactions on 2025-11-05, reducing holdings 58.6%.

Evan Jones, a director at Veracyte, executed 6 separate sales totaling 43,196 shares for $1,946,287.73 at prices ranging from $41.74 to $46.38, reducing his stake from 73,664 shares to 30,468 shares (a -58.6% net change in holdings). The blended average sale price of $45.06 sits near the 52-week high of $46.14, and the stock is currently trading at $41.70 (down 9.6% from the 52-week high). Across his prior 5 trades at Veracyte, all conducted on 2024-08-13, none were well-timed at the 90-day mark, with post-sale returns ranging from +18.7% to +24.7%—meaning the stock subsequently appreciated after each prior sale. This transaction size (43.2K shares) represents a material portfolio reduction and occurs at elevated price levels relative to recent ranges.

Director Evan Jones sells 47,845 shares ($1.5M) across 8 transactions, reducing stake by 90.2% to 5,173 shares remaining

Evan Jones, a Veracyte director, executed 8 separate sales totaling 47,845 shares for $1,540,366.41 on August 12–13, 2024, at blended average price of $32.19. This represents a dramatic 90.2% reduction in his holdings from 53,018 shares to 5,173 shares. Notably, his prior trade history at VCYT shows a 100% well-timed sell rate across 4 prior transactions, with consistent negative 90-day returns ranging from -29.2% to -29.5%, suggesting a demonstrated ability to exit ahead of declines at this ticker. The stock has appreciated 38.1% over the past 30 days and 33.3% over 90 days from prior levels, placing the current price at $31.19, only 4.2% below the 52-week high of $32.55—a level near where Jones executed the majority of his sales. The company is growing revenue at 21.8% annually but remains unprofitable on a full-year basis despite recent quarterly profitability of $5.7M, creating potential tension between growth narrative and underlying unit economics that warrant investor scrutiny.